Pubblicazioni

Documenti scaricabili

Nome Numero di download Versione Ultima modifica Valutazione
Nome Numero di download Versione Ultima modifica Valutazione
71 file scaricati 1.0 16-06-2021 18:16
368 file scaricati 1.0 15-03-2021 19:32
136 file scaricati 1.0 15-03-2021 15:47
561 file scaricati 1.0 08-01-2019 22:11
704 file scaricati 1.0 24-09-2018 17:15
852 file scaricati 1.0 24-09-2018 17:14
391 file scaricati 1.0 24-09-2018 17:03
342 file scaricati 1.0 24-09-2018 17:02
604 file scaricati 1.0 25-07-2018 16:09
510 file scaricati 1.0 16-07-2018 17:27
368 file scaricati 1.0 22-02-2018 13:00
480 file scaricati 1.0 22-02-2018 13:00

Pubblicazioni Vironet C

  • Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network Vironet-C. Liver Int. 2021 Jan 26. doi: 10.1111/liv.14797. Online ahead of print. PMID: 33497016
    https://www.ncbi.nlm.nih.gov/pubmed/33497016
  • Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2020 Nov 19:S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017. Online ahead of print. PMID: 33220331
    https://www.ncbi.nlm.nih.gov/pubmed/33220331
  • de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentavir regimen. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. PMID: 32772078
    https://www.ncbi.nlm.nih.gov/pubmed/32772078
  • Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F1; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 Jun 12;8(1):8988.
    https://www.ncbi.nlm.nih.gov/pubmed/29895871
  •  
  • Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian  Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol. 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep20. PubMed PMID: 28939133.
    https://www.ncbi.nlm.nih.gov/pubmed/28939133
  • Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 1;72(12):3420-3424. doi: 10.1093/jac/dkx302. PubMed PMID: 28961921. https://www.ncbi.nlm.nih.gov/pubmed/28961921
  • Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. PubMed PMID: 26679249.
    https://www.ncbi.nlm.nih.gov/pubmed/26679249
  •  
  • Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clin Microbiol Infect. 2017 Oct;23(10):777.e1-777.e4. doi: 10.1016/j.cmi.2017.04.005. Epub 2017 Apr 12. PubMed PMID: 28412381.
    https://www.ncbi.nlm.nih.gov/pubmed/?term=ceccherini+silberstein+cento+lenci+optimal
  • Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. PubMed PMID: 28105744.
    https://www.ncbi.nlm.nih.gov/pubmed/28105744

Altre pubblicazioni utili

2020

  • Salpini R, Piermatteo L, Battisti A, Colagrossi L, Aragri M, Yu La Rosa K,Bertoli A, Saccomandi P, Lichtner M, Marignani M, Maylin S, Delaugerre C, MoriscoF, Coppola N, Marrone A, Iapadre N, Cerva C, Aquaro S, Angelico M, Sarmati L,Andreoni M, Verheyen J, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L,Svicher V. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. Viruses. 2020 Feb 23;12(2):251.
    https://www.ncbi.nlm.nih.gov/pubmed/32102257
  • Aragri M, Milana M, Di Maio VC, Lenci I, Carioti L, Perno CF, Svicher V, Angelico M, Ceccherini-Silberstein F. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Clin Microbiol Infect. 2020 Sep;26(9):1266-1268.
    https://www.ncbi.nlm.nih.gov/pubmed/32240711
  • Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms. 2020 Nov; 8(11): 1819.
    https://www.ncbi.nlm.nih.gov/pubmed/33218205
  • Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, Yu La Rosa K, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, Kennedy PT, Verheyen J, Aquaro S, Ceccherini-Silberstein F, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerg Microbes Infect. 2020; 9(1): 928–939.
    https://www.ncbi.nlm.nih.gov/pubmed/32312174
  • Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut. 2020 Dec 21:gutjnl-2020-323300.
    https://www.ncbi.nlm.nih.gov/pubmed/33402415
  • Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J Hepatol. 2020;73:794–799.
    https://www.ncbi.nlm.nih.gov/pubmed/3270499
  • Papaluca T, Roberts SK, Strasser SI, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1318
    https://www.ncbi.nlm.nih.gov/pubmed/32887983
  • Singh AD, Maitra S, Singh N, et al. Systematic review and meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther. 2020;1–15. doi:10.1111/apt.15633
    https://www.ncbi.nlm.nih.gov/pubmed/31943236

2019

  • Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J Viral Hepat. 2019 Jul;26(7):846-855.
    https://www.ncbi.nlm.nih.gov/pubmed/30974483
  • Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. The novel HBx mutation F30V correlates with HCC in vivo, reduces HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro. Clin Microbiol Infect. 2019 Jul;25(7):906.e1-906.e7.
    https://www.ncbi.nlm.nih.gov/pubmed/30472417
  • Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions. Viruses. 2019. doi:10.3390/v11020148
    https://www.ncbi.nlm.nih.gov/pubmed/30754682
  • Papaluca T, O’Keefe J, Bowden S, et al. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol. 2019;120:84–87 .
    https://www.ncbi.nlm.nih.gov/pubmed/31606586
  • Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. Expert Rev AntiInfect Ther. 2019 Feb;17(2):117-128. IF 1.87
    https://www.ncbi.nlm.nih.gov/pubmed/30582384
  • Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int. 2019 Oct;39(10):1986-1998. IF 5.542
    https://www.ncbi.nlm.nih.gov/pubmed/31172639
  • Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells. 2019 Jul 2;8(7). IF 5.656
    https://www.ncbi.nlm.nih.gov/pubmed/31269695
  • Smith D, Magri A, Bonsall D, et al. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology. 2019. doi:10.1002/hep.29837.
    https://www.ncbi.nlm.nih.gov/pubmed/29425396
  • Childs K, Davis C, Cannon M, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. J Hepatol. 2019;71:1099–1105.
    https://www.ncbi.nlm.nih.gov/pubmed/31400349
  • Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019. doi:10.1016/j.jhep.2019.06.002
    https://www.ncbi.nlm.nih.gov/pubmed/31203153

2018

  • Leone S, Shanyinde M, Cozzi Lepri A, Lampe FC, Caramello P, Costantini A, Giacometti A, De Luca A, Cingolani A, Ceccherini Silberstein F, Puoti M, Gori A, d’Arminio Monforte A; ICONA Foundation Cohort Study. Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis. 2018 May;37(5):871-881
    https://www.ncbi.nlm.nih.gov/pubmed/29318459
  • Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection. 2018 Oct;46(5):717-720
    https://www.ncbi.nlm.nih.gov/pubmed/29804205
  • Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses. 2018 Jul 9;10(7).
    https://www.ncbi.nlm.nih.gov/pubmed/29987240
  • Popping S, Cento V, García F, Ceccherini-Silberstein F, Seguin-Devaux C, Vijver DA, Boucher CA. The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. J Virus Erad. 2018 Jul 1;4(3):179-181.
    https://www.ncbi.nlm.nih.gov/pubmed/30050681
  • Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol. 2018 Oct;32:115-127 https://www.ncbi.nlm.nih.gov/pubmed/30439589
    Borgia SM, Hedskog C, Parhy B, et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018. doi:10.1093/infdis/jiy401
    https://www.ncbi.nlm.nih.gov/pubmed/29982508
  • Asselah T, Bourgeois S, Pianko S, et al.: Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int 2018 Mar, 38:443–450.
    https://www.ncbi.nlm.nih.gov/pubmed/28756625
  • Calvaruso V, Cabibbo G, Cacciola I, et al.: Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441-4.
    https://www.ncbi.nlm.nih.gov/pubmed/29655836
  • Calvaruso V, Ferraro D, Licata A, et al.: HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018 Jan;25(1):72-79.
    https://www.ncbi.nlm.nih.gov/pubmed/28703895
  • Caudai C, Materazzi A, Saladini F, et al.: Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect. 2018 Mar;24(3):308.e5-308.e8.
    https://www.ncbi.nlm.nih.gov/pubmed/28811242
  • Dietz J, Susser S, Vermehren J, et al.: Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology 2018 Mar, 154:976–988.
    https://www.ncbi.nlm.nih.gov/pubmed/29146520
  • Harrington PR, Komatsu TE, Deming DJ, et al.: Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018 Jun, 67:2430–2448.
    https://www.ncbi.nlm.nih.gov/pubmed/29194682
  • Hezode C, Reau N, Svarovskaia ES, et al.: Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018 May, 68:895–903.
    https://www.ncbi.nlm.nih.gov/pubmed/29221887
  • Omar H, El Akel W, Elbaz T, et al.: Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. AlimentPharmacolTher 2018 Feb, 47:421–431.
    https://www.ncbi.nlm.nih.gov/pubmed/29193226
  • Palanisamy N, Kalaghatgi P, Akaberi D, et al.: Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther 2018 May.
    https://www.ncbi.nlm.nih.gov/pubmed/29745936
  • Papatheodoridis GV, Hatzakis A, Cholongitas E, et al.: Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018 Mar;25 Suppl 1:6-17.
    https://www.ncbi.nlm.nih.gov/pubmed/29508946
  • Petta S, Adinolfi LE, Fracanzani AL, et al.: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018 Jul. pii: S0168-8278(18)30132-6.
    https://www.ncbi.nlm.nih.gov/pubmed/29505844
  • Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403.
    https://www.ncbi.nlm.nih.gov/pubmed/29599078
  • Puoti M, Foster GR, Wang S, et al.: High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. J Hepatol 2018 Mar
    https://www.ncbi.nlm.nih.gov/pubmed/29551706
  • Smith D, Magri A, Bonsall D, et al.: Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2018 Feb,
    https://www.ncbi.nlm.nih.gov/pubmed/29425396
  • Sorbo MC, Cento V, Di Maio VC, et al.: Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist 2018 Mar, 37:17–39.
    https://www.ncbi.nlm.nih.gov/pubmed/29525636

2017

  • Bartlett SR, Grebely J, Eltahla AA, et al.: Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatol Commun. 2017 May 22;1(5):379-390.
    https://www.ncbi.nlm.nih.gov/pubmed/29404466
  • Cento V, Nguyen THT, Di Carlo D, et al.: Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017 May 18;12(5):e0177352.
    https://www.ncbi.nlm.nih.gov/pubmed/28545127
  • Cuypers L, Libin P, Schrooten Y, et al.: Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infect Genet Evol. 2017 Sep;53:15-23.
    https://www.ncbi.nlm.nih.gov/pubmed/28499845
  • Cuypers L, Vrancken B, Fabeni L, et al.: Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evol Biol. 2017 Mar 7;17(1):70. https://www.ncbi.nlm.nih.gov/pubmed/28270091
  • d’Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, et al.: Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017 May 17;12(5):e0177402.
    https://www.ncbi.nlm.nih.gov/pubmed/28520749
  • Karampatou A, Han X, Kondili LA, et al.: Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32259-6.
    https://www.ncbi.nlm.nih.gov/pubmed/28882581
  • Komatsu TE, Boyd S, Sherwat A, et al.: Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017 Feb, 152:586–597.
    https://www.ncbi.nlm.nih.gov/pubmed/27773808
  • Kondili LA, Gaeta GB, Brunetto MR, et al.: Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017 Oct 4;12(10):e0185728.
    https://www.ncbi.nlm.nih.gov/pubmed/28977040
  • Lembo T, Saffioti F, Chiofalo B, et al.: Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017 Dec; 49(12):1368-1372.
    https://www.ncbi.nlm.nih.gov/pubmed/28818677
  • Lenci I, Bosa A, Milana M, et al.: Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci. 2017 Aug;62(8):2193-2195. https://www.ncbi.nlm.nih.gov/pubmed/28500586
  • Maimone S, Caccamo G, Squadrito G, et al.:A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int. 2017 Mar;37(3):362-368.
    https://www.ncbi.nlm.nih.gov/pubmed/27606573
  • Pellicelli AM, Pace Palitti V, Vignally P, et al.: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver Int. 2017 May;37(5):653-661.
    https://www.ncbi.nlm.nih.gov/pubmed/27782373
  • Petta S, Marzioni M, Russo P, et al.: Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434.
    https://www.ncbi.nlm.nih.gov/pubmed/28497758
  • Puoti M, Lorenzini P, Cozzi-Lepri A, et al.: Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4.
    https://www.ncbi.nlm.nih.gov/pubmed/27956268
  • Struble K, Chan-Tack K, Qi K, et al.: Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration’s evaluation. Hepatology 2017 Oct, 67:482–491.
    https://www.ncbi.nlm.nih.gov/pubmed/29059462
  • Welzel TM, Bhardwaj N, Hedskog C, et al.: Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol 2017 Aug, 67:224–236.
    https://www.ncbi.nlm.nih.gov/pubmed/28343981

2016

  • Ceccherini Silberstein F, Di Maio VC, Aragri M, et al.: Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2016 Mar;63(3):1058-9.
    https://www.ncbi.nlm.nih.gov/pubmed/25974082
  • Chen ZW, Li H, Ren H, et al.: Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. SciRep 2016 Feb, 6:20310.
    https://www.ncbi.nlm.nih.gov/pubmed/26842909

2015

2014

  • Di Maio VC, Cento V, Mirabelli C, et al.: Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014 May;58(5):2781-97.
    https://www.ncbi.nlm.nih.gov/pubmed/24590484

Promuovere la ricerca. Tante possibilità. Infinite opportunità.

Gli amici di VIRONET C ONLUS Il progetto beneficia di sponsorizzazioni non condizionanti